Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Study measures impact of epilepsy drugs in utero

A review highlights the risks that women with epilepsy need to consider when taking medication and becoming pregnant. 


Source: Getty

Researchers recommend that women with epilepsy should be made aware of the risks associated with their medication before becoming pregnant

Women with epilepsy should be warned upon diagnosis that some treatments for the condition may have adverse effects on the neurodevelopment of unborn babies. 

These women should also be told about alternative treatment options so that they are well informed before they become pregnant, says Rebecca Bromley from the Institute of Human Development at the University of Manchester, the lead researcher behind a drug review published on 29 October 2014 in the Cochrane Database of Systematic Reviews[1]

Many pregnancies are unplanned and women should be counselled on the balance between the neurodevelopment of an unborn child and the needs of the mother to control seizures, Bromley says. 

The researchers looked at the results of 28 studies and the neurodevelopment of children born to women with epilepsy and their prenatal exposure to commonly prescribed anti-epileptic drugs. 

They measured children’s global cognitive ability using intelligence quotient (IQ) for school aged children and developmental quotient (DQ) for younger children. They looked at DQ and IQ scores in the children of three groups – women with epilepsy who took anti-epilepsy medication, those with epilepsy who did not take drugs and women who did not have epilepsy.

The researchers found that the children of women who took sodium valproate had lower DQs and IQs than the children of women in the other two groups. Higher doses of the drug were linked to larger effects on IQ or DQ.

But they advise that most women with epilepsy should continue their treatment when pregnant because uncontrolled seizures also carry a maternal risk.

The researchers also discovered that the anti-epileptic drug carbamazepine did not appear to have any significant effects on DQ or IQ. Although younger children born to women who took carbamazepine did have lower DQs, the researchers say this was due to “random variation” between the results of studies.

They found that the children of women who took valproate had lower IQs than children exposed to carbamazepine or lamotrigine in the womb. They also had lower DQs and IQs than children born to women who took phenytoin. There were no differences between the IQs of children exposed to either carbamazepine, phenytoin or lamotrigine, they found. 

“The most important finding is the reduction in IQ in the sodium valproate exposed group, which are sufficient to affect education and occupational outcomes in later life,” the researchers conclude. 

Kathy Bairstow, senior advice and information services officer for the patient charity Epilepsy Action, said the findings confirmed what women already know. “Pregnancy can be a huge issue for women with epilepsy and can be quite difficult in cases where sodium valproate is the only drug that controls your seizures with the fewest side effects,” she says. “Women will be guided by their epilepsy specialist or nurse and it’s really important that they get pre-conception counselling.” 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066991

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.